Allied Market Research
Loading...
0
New
New
2022
Congestive Heart Failure (chf) Treatment Devices Market

Congestive Heart Failure (CHF) Treatment Devices Market by Product Type (Pacemakers, Cardiac Resynchronization Therapy, Implantable Cardioverter Defibrillators, Ventricular Assist Devices): Global Opportunity Analysis and Industry Forecast, 2020-2030

A00541
Pages: 220
May 2022 | 12118 Views
   
Author(s) : Monika Darandale , Onkar Sumant
Tables: 88
Charts: 52
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Congestive Heart Failure (chf) Treatment Devices Market

Request Now !

Congestive Heart Failure (CHF) Treatment Devices Market Research, 2030

The global congestive heart failure treatment devices market was valued at $11.9 billion in 2020, and is projected to reach $20.5 billion by 2030, growing at a CAGR of 5.6% from 2021 to 2030.

Congestive heart failure treatment device is known as mechanical circulatory support device. There are different types of congestive heart failure treatment devices such as, pacemakers, cardiac resynchronization therapy devices, implantable cardioverter defibrillators, and ventricular assist devices. The implantable cardiac defibrillator is an electronic device that is placed inside the body. An ICD (implantable cardiac defibrillator) constantly keeps track of heart rhythm and sends a small shock to the heart muscle if the rhythm becomes abnormal. A ventricular assist is a device that helps to pump the blood from the lower chambers of heart to the rest of the human body. In addition, there are different types of ventricular assist devices, such as left congestive heart failure treatment devices(LVADs), right congestive heart failure treatment devices(RVADs), and others. Left congestive heart failure treatment devicesare the most widely used VADs, as the prevalence of weak left ventricle muscles is common among the affected patients. They have been used as a permanent solution in patients who have minor chances of improvement of cardiac muscles. Right congestive heart failure treatment devices(RVADs) are used to pump blood to the pulmonary aorta from the right ventricle. Such cases are relatively rare as compared to the cases with need of LVAD.

The COVID-19 pandemic has restrained the industry growth significantly due to decrease in number of cardiac surgeries has led to decline in the usage and production of congestive heart failure treatment devices.

Congestive Heart Failure Treatment Devices Market, CHF Treatment Devices Market, Congestive Heart Failure Treatment Devices Market size, Congestive Heart Failure Treatment Devices Market share, Congestive Heart Failure Treatment Devices Market trends, Congestive Heart Failure Treatment Devices Market growth, Congestive Heart Failure Treatment Devices Market forecast, Congestive Heart Failure Treatment Devices Market opportunity

Get more information on this report : Request Sample Pages

Growth of the global CHF treatment devices market is majorly driven by rise in prevalence of cardiovascular disorders, increase in risk of organ failure, and development of new congestive heart failure treatment devices by large number of heart failure device companies. According to Organ Procurement and Transplantation Network, 3,582 candidates were registered on the waiting list for heart transplant as of June 2020 in the U.S. Thus, rise in number of patient with heart failure has increased the demand for ventricular assist devices, which is anticipated to foster the growth of the market and provide congestive heart failure treatment devices market opportunity. Furthermore, surge in geriatric population has increased the number of cardiovascular disease cases, and rise in shortage of organ donors are some congestive heart failure treatment devices market trends which further fuel growth of the market. According to World Health Organization, it is estimated that 17.9 million people died from cardiovascular disease in 2019. Thus, upsurge in burden of cardiovascular diseases and increased rate of heart failure are anticipated to boost the growth of the market. Furthermore, rise in number of product approvals is expected to provide remunerative opportunities for the congestive heart failure treatment devices market growth.

The COVID-19 outbreak is anticipated to have a negative impact on the growth of the global congestive heart failure treatment devices market. According to Society of Thoracic Surgeons, there was sharp reduction of adult cardiac surgery volumes during the first wave of the pandemic. The Mid-Atlantic area (New York, New Jersey, and Pennsylvania) was among the hardest hit during the first surge of the COVID pandemic, experiencing a 71% decrease in overall cardiac surgery case volume. In addition, the COVID-19 pandemic has stressed the healthcare system in the world. A huge number of clinics and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. This led to cancellation of many non-essential surgical procedures across the world. Moreover, according to American College of Cardiology, surveys were submitted from 909 inpatient and outpatient centers performing cardiac diagnostic procedures in 108 countries. According to researchers, procedure volumes decreased 42% from March 2019 to March 2020, and 64% from March 2019 to April 2020. Thus, decrease in number of cardiac surgeries has led to decline in the usage and production of congestive heart failure treatment devices, which has restricted the growth during congestive heart failure treatment devices market forecast.

In addition,the market is restrained by high cost of the procedure and certain risks associated with the congestive heart failure treatment devices.

Congestive Heart Failure (CHF) Treatment Devices Market Segmentation

The congestive heart failure treatment devices market is segmented on the basis of product and region. On the basis of product, it is divided into pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillator (ICDs), and ventricular assist device (VADs).Pacemaker is further bifurcated into implantable pacemaker and external pacemakers. In addition, CRT devices segment is segmented into two major types, namely, CRT-P and CRT-D. Furthermore, ICDs is further segmented into transvenous implantable cardioverter defibrillator (T-ICDs) and subcutaneous implantable cardioverter defibrillator (S-ICDs). Moreover, VADs is also segmented into left ventricular assist device (LVAD), right ventricular assist device (RVAD), and biventricular assist device (BIVAD).                                                   

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment review

Depending on product, the pacemakers segment dominated the congestive heart failure treatment devices market size in 2020, and this trend is expected to continue during the forecast period, owing to increase in R&D activities in the pharmaceutical & medical device industry, rise in demand for congestive heart failure treatment devices for the treatment of heart failure, and surge in adoption of pacemakers. However, the ventricular assist device segment is expected to witness considerable growth during the forecast period, owing to upsurge in number of cardiac surgeries and rise in number of key players for development of congestive heart failure treatment devices in the medical device industry.

North America garnered largest congestive heart failure treatment devices market share in 2020, and is expected to continue to dominate during the forecast period, owing to rise in number of cardiac surgeries, presence of key players, development of the healthcare sector, and presence of new innovative ventricular assist and devices products in the region. However, Asia-Pacific is expected to register the highest CAGR of 6.2% in congestive heart failure treatment devices Market size, owing to surge in use for lifetime support and development of healthcare infrastructure.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the congestive heart failure (chf) treatment devices market analysis from 2020 to 2030 to identify the prevailing congestive heart failure (chf) treatment devices market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the congestive heart failure (chf) treatment devices market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global congestive heart failure (chf) treatment devices market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

  • By Product Type
    • Pacemakers
    • Cardiac Resynchronization Therapy
    • Implantable Cardioverter Defibrillators
    • Ventricular Assist Devices
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • U.K.
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA


Key Market Players

  • abbot laboratories
  • Abiomed Inc.
  • Berlin Heart GmbH
  • Biotronik SE and Co. KG
  • Boston Scientific Corporation
  • Jarvik Heart Inc
  • Lepu Medical
  • Medtronic Plc
  • Microport Scientific Corporation
  • Osypka Medical GmbH
 
  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY PRODUCT TYPE

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Pacemakers

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Cardiac Resynchronization Therapy

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

    • 4.4 Implantable Cardioverter Defibrillators

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market analysis by country

    • 4.5 Ventricular Assist Devices

      • 4.5.1 Key market trends, growth factors and opportunities

      • 4.5.2 Market size and forecast, by region

      • 4.5.3 Market analysis by country

  • CHAPTER 5: CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY REGION

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 North America

      • 5.2.1 Key trends and opportunities

      • 5.2.2 North America Market size and forecast, by Product Type

      • 5.2.3 North America Market size and forecast, by country

        • 5.2.3.1 U.S.
          • 5.2.3.1.1 Market size and forecast, by Product Type
        • 5.2.3.2 Canada
          • 5.2.3.2.1 Market size and forecast, by Product Type
        • 5.2.3.3 Mexico
          • 5.2.3.3.1 Market size and forecast, by Product Type
    • 5.3 Europe

      • 5.3.1 Key trends and opportunities

      • 5.3.2 Europe Market size and forecast, by Product Type

      • 5.3.3 Europe Market size and forecast, by country

        • 5.3.3.1 Germany
          • 5.3.3.1.1 Market size and forecast, by Product Type
        • 5.3.3.2 France
          • 5.3.3.2.1 Market size and forecast, by Product Type
        • 5.3.3.3 U.K.
          • 5.3.3.3.1 Market size and forecast, by Product Type
        • 5.3.3.4 Italy
          • 5.3.3.4.1 Market size and forecast, by Product Type
        • 5.3.3.5 Spain
          • 5.3.3.5.1 Market size and forecast, by Product Type
        • 5.3.3.6 Rest of Europe
          • 5.3.3.6.1 Market size and forecast, by Product Type
    • 5.4 Asia-Pacific

      • 5.4.1 Key trends and opportunities

      • 5.4.2 Asia-Pacific Market size and forecast, by Product Type

      • 5.4.3 Asia-Pacific Market size and forecast, by country

        • 5.4.3.1 Japan
          • 5.4.3.1.1 Market size and forecast, by Product Type
        • 5.4.3.2 China
          • 5.4.3.2.1 Market size and forecast, by Product Type
        • 5.4.3.3 India
          • 5.4.3.3.1 Market size and forecast, by Product Type
        • 5.4.3.4 Australia
          • 5.4.3.4.1 Market size and forecast, by Product Type
        • 5.4.3.5 South Korea
          • 5.4.3.5.1 Market size and forecast, by Product Type
        • 5.4.3.6 Rest of Asia-Pacific
          • 5.4.3.6.1 Market size and forecast, by Product Type
    • 5.5 LAMEA

      • 5.5.1 Key trends and opportunities

      • 5.5.2 LAMEA Market size and forecast, by Product Type

      • 5.5.3 LAMEA Market size and forecast, by country

        • 5.5.3.1 Brazil
          • 5.5.3.1.1 Market size and forecast, by Product Type
        • 5.5.3.2 Saudi Arabia
          • 5.5.3.2.1 Market size and forecast, by Product Type
        • 5.5.3.3 South Africa
          • 5.5.3.3.1 Market size and forecast, by Product Type
        • 5.5.3.4 Rest of LAMEA
          • 5.5.3.4.1 Market size and forecast, by Product Type
  • CHAPTER 6: COMPANY LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top winning strategies

    • 6.3. Product Mapping of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Key developments

  • CHAPTER 7: COMPANY PROFILES

    • 7.1 abbot laboratories

      • 7.1.1 Company overview

      • 7.1.2 Company snapshot

      • 7.1.3 Operating business segments

      • 7.1.4 Product portfolio

      • 7.1.5 Business performance

      • 7.1.6 Key strategic moves and developments

    • 7.2 Abiomed Inc.

      • 7.2.1 Company overview

      • 7.2.2 Company snapshot

      • 7.2.3 Operating business segments

      • 7.2.4 Product portfolio

      • 7.2.5 Business performance

      • 7.2.6 Key strategic moves and developments

    • 7.3 Berlin Heart GmbH

      • 7.3.1 Company overview

      • 7.3.2 Company snapshot

      • 7.3.3 Operating business segments

      • 7.3.4 Product portfolio

      • 7.3.5 Business performance

      • 7.3.6 Key strategic moves and developments

    • 7.4 Biotronik SE and Co. KG

      • 7.4.1 Company overview

      • 7.4.2 Company snapshot

      • 7.4.3 Operating business segments

      • 7.4.4 Product portfolio

      • 7.4.5 Business performance

      • 7.4.6 Key strategic moves and developments

    • 7.5 Boston Scientific Corporation

      • 7.5.1 Company overview

      • 7.5.2 Company snapshot

      • 7.5.3 Operating business segments

      • 7.5.4 Product portfolio

      • 7.5.5 Business performance

      • 7.5.6 Key strategic moves and developments

    • 7.6 Jarvik Heart Inc

      • 7.6.1 Company overview

      • 7.6.2 Company snapshot

      • 7.6.3 Operating business segments

      • 7.6.4 Product portfolio

      • 7.6.5 Business performance

      • 7.6.6 Key strategic moves and developments

    • 7.7 Lepu Medical

      • 7.7.1 Company overview

      • 7.7.2 Company snapshot

      • 7.7.3 Operating business segments

      • 7.7.4 Product portfolio

      • 7.7.5 Business performance

      • 7.7.6 Key strategic moves and developments

    • 7.8 Medtronic Plc

      • 7.8.1 Company overview

      • 7.8.2 Company snapshot

      • 7.8.3 Operating business segments

      • 7.8.4 Product portfolio

      • 7.8.5 Business performance

      • 7.8.6 Key strategic moves and developments

    • 7.9 Microport Scientific Corporation

      • 7.9.1 Company overview

      • 7.9.2 Company snapshot

      • 7.9.3 Operating business segments

      • 7.9.4 Product portfolio

      • 7.9.5 Business performance

      • 7.9.6 Key strategic moves and developments

    • 7.10 Osypka Medical GmbH

      • 7.10.1 Company overview

      • 7.10.2 Company snapshot

      • 7.10.3 Operating business segments

      • 7.10.4 Product portfolio

      • 7.10.5 Business performance

      • 7.10.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
    TABLE 2. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET REVENUE, FOR PACEMAKERS, BY REGION , 2020-2030,($MILLION)
    TABLE 3. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET PACEMAKERS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 4. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET REVENUE, FOR CARDIAC RESYNCHRONIZATION THERAPY, BY REGION , 2020-2030,($MILLION)
    TABLE 5. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET CARDIAC RESYNCHRONIZATION THERAPY BY COUNTRY, 2020-2030,($MILLION)
    TABLE 6. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET REVENUE, FOR IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY REGION , 2020-2030,($MILLION)
    TABLE 7. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET IMPLANTABLE CARDIOVERTER DEFIBRILLATORS BY COUNTRY, 2020-2030,($MILLION)
    TABLE 8. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET REVENUE, FOR VENTRICULAR ASSIST DEVICES, BY REGION , 2020-2030,($MILLION)
    TABLE 9. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET VENTRICULAR ASSIST DEVICES BY COUNTRY, 2020-2030,($MILLION)
    TABLE 10. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY REGION, 2020-2030,($MILLION)
    TABLE 11. NORTH AMERICA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
    TABLE 12. NORTH AMERICA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 13. U.S. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 14. CANADA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 15. MEXICO CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 16. EUROPE CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
    TABLE 17. EUROPE CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 18. GERMANY CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 19. FRANCE CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 20. U.K. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 21. ITALY CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 22. SPAIN CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 23. REST OF EUROPE CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 24. ASIA-PACIFIC CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
    TABLE 25. ASIA-PACIFIC CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 26. JAPAN CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 27. CHINA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 28. INDIA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 29. AUSTRALIA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 30. SOUTH KOREA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 31. REST OF ASIA-PACIFIC CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 32. LAMEA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY PRODUCT TYPE, 2020-2030,($MILLION)
    TABLE 33. LAMEA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY COUNTRY, 2020-2030,($MILLION)
    TABLE 34. BRAZIL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 35. SAUDI ARABIA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 36. SOUTH AFRICA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 37. REST OF LAMEA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY PRODUCT TYPE 2020-2030,($MILLION)
    TABLE 38.ABBOT LABORATORIES: COMPANY SNAPSHOT
    TABLE 39.ABBOT LABORATORIES: OPERATING SEGMENTS
    TABLE 40.ABBOT LABORATORIES: PRODUCT PORTFOLIO
    TABLE 41.ABBOT LABORATORIES: NET SALES,
    TABLE 42.ABBOT LABORATORIES: KEY STRATERGIES
    TABLE 43.ABIOMED INC.: COMPANY SNAPSHOT
    TABLE 44.ABIOMED INC.: OPERATING SEGMENTS
    TABLE 45.ABIOMED INC.: PRODUCT PORTFOLIO
    TABLE 46.ABIOMED INC.: NET SALES,
    TABLE 47.ABIOMED INC.: KEY STRATERGIES
    TABLE 48.BERLIN HEART GMBH: COMPANY SNAPSHOT
    TABLE 49.BERLIN HEART GMBH: OPERATING SEGMENTS
    TABLE 50.BERLIN HEART GMBH: PRODUCT PORTFOLIO
    TABLE 51.BERLIN HEART GMBH: NET SALES,
    TABLE 52.BERLIN HEART GMBH: KEY STRATERGIES
    TABLE 53.BIOTRONIK SE AND CO. KG: COMPANY SNAPSHOT
    TABLE 54.BIOTRONIK SE AND CO. KG: OPERATING SEGMENTS
    TABLE 55.BIOTRONIK SE AND CO. KG: PRODUCT PORTFOLIO
    TABLE 56.BIOTRONIK SE AND CO. KG: NET SALES,
    TABLE 57.BIOTRONIK SE AND CO. KG: KEY STRATERGIES
    TABLE 58.BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
    TABLE 59.BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
    TABLE 60.BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
    TABLE 61.BOSTON SCIENTIFIC CORPORATION: NET SALES,
    TABLE 62.BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES
    TABLE 63.JARVIK HEART INC: COMPANY SNAPSHOT
    TABLE 64.JARVIK HEART INC: OPERATING SEGMENTS
    TABLE 65.JARVIK HEART INC: PRODUCT PORTFOLIO
    TABLE 66.JARVIK HEART INC: NET SALES,
    TABLE 67.JARVIK HEART INC: KEY STRATERGIES
    TABLE 68.LEPU MEDICAL: COMPANY SNAPSHOT
    TABLE 69.LEPU MEDICAL: OPERATING SEGMENTS
    TABLE 70.LEPU MEDICAL: PRODUCT PORTFOLIO
    TABLE 71.LEPU MEDICAL: NET SALES,
    TABLE 72.LEPU MEDICAL: KEY STRATERGIES
    TABLE 73.MEDTRONIC PLC: COMPANY SNAPSHOT
    TABLE 74.MEDTRONIC PLC: OPERATING SEGMENTS
    TABLE 75.MEDTRONIC PLC: PRODUCT PORTFOLIO
    TABLE 76.MEDTRONIC PLC: NET SALES,
    TABLE 77.MEDTRONIC PLC: KEY STRATERGIES
    TABLE 78.MICROPORT SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
    TABLE 79.MICROPORT SCIENTIFIC CORPORATION: OPERATING SEGMENTS
    TABLE 80.MICROPORT SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
    TABLE 81.MICROPORT SCIENTIFIC CORPORATION: NET SALES,
    TABLE 82.MICROPORT SCIENTIFIC CORPORATION: KEY STRATERGIES
    TABLE 83.OSYPKA MEDICAL GMBH: COMPANY SNAPSHOT
    TABLE 84.OSYPKA MEDICAL GMBH: OPERATING SEGMENTS
    TABLE 85.OSYPKA MEDICAL GMBH: PRODUCT PORTFOLIO
    TABLE 86.OSYPKA MEDICAL GMBH: NET SALES,
    TABLE 87.OSYPKA MEDICAL GMBH: KEY STRATERGIES
  • LIST OF FIGURES

  • FIGURE 1.CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET SEGMENTATION
    FIGURE 2.CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030
    FIGURE 3.CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,BY PRODUCT TYPE,2020(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF PACEMAKERS CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CARDIAC RESYNCHRONIZATION THERAPY CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF VENTRICULAR ASSIST DEVICES CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030(%)
    FIGURE 17.CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET BY REGION,2020
    FIGURE 18.U.S. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 19.CANADA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 20.MEXICO CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 21.GERMANY CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 22.FRANCE CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 23.U.K. CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 24.ITALY CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 25.SPAIN CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 26.REST OF EUROPE CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 27.JAPAN CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 28.CHINA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 29.INDIA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 30.AUSTRALIA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 31.SOUTH KOREA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 32.REST OF ASIA-PACIFIC CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 33.BRAZIL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 34.SAUDI ARABIA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 35.SOUTH AFRICA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 36.REST OF LAMEA CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET,2020-2030($MILLION)
    FIGURE 37. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 40.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 41.COMPETITIVE DASHBOARD
    FIGURE 42.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 43.ABBOT LABORATORIES.: NET SALES ,($MILLION)
    FIGURE 44.ABIOMED INC..: NET SALES ,($MILLION)
    FIGURE 45.BERLIN HEART GMBH.: NET SALES ,($MILLION)
    FIGURE 46.BIOTRONIK SE AND CO. KG.: NET SALES ,($MILLION)
    FIGURE 47.BOSTON SCIENTIFIC CORPORATION.: NET SALES ,($MILLION)
    FIGURE 48.JARVIK HEART INC.: NET SALES ,($MILLION)
    FIGURE 49.LEPU MEDICAL.: NET SALES ,($MILLION)
    FIGURE 50.MEDTRONIC PLC.: NET SALES ,($MILLION)
    FIGURE 51.MICROPORT SCIENTIFIC CORPORATION.: NET SALES ,($MILLION)
    FIGURE 52.OSYPKA MEDICAL GMBH.: NET SALES ,($MILLION)

 
 

The utilization of CHF treatment devices is likelyto witness a significant rise with increased diagnosis of arrhythmias and heart failures. CHF treatment devices market has piqued the interest of healthcare providers due to several benefits offered by these devices to monitor and treat irregular heart rhythm coupled with the evolving indications for CHF treatment devices. There have been remarkable technological advancements in CHF treatment devices to provide advanced treatment options for the management of cardiac rhythm of heart patients. As the market is saturated and is growing at a steady rate in developed nations, Asia-Pacific and LAMEA are expected to offer high growth opportunities to the key players in this market.

 

Greater consumer awareness &demand for preventive healthcare services, escalating demand for healthcare services from overall population, and new advancements are predicted to broaden congestive heart failure treatment devices clinical applications and increase the number of product approvals. Furthermore, use of congestive heart failure treatment devices for lifetime support contributestoward growth of the market.

 

The market gains interest of healthcare companies, owing to focus on preventive facilities provided to patients who undergo critical pulmonary surgeries, which are more complex than other health conditions. This leads to increase in utilization of congestive heart failure treatment devices; thus creating a great opportunity to further propel the growth of the market.

 

North America is expected to witness highest growth, in terms of revenue, owing to rise in geriatric population, presence of key players, and advancements in healthcare investments. However, Asia-Pacific was the third largest contributor to the market in 2020, and is expected to register fastest CAGR during the forecast period, owing to increase in number of cardiovascular surgeries and unmet needs for advanced congestive heart failure treatment devices. However, high cost associated with congestive heart failure treatment devices are expected to restrain the market growth during the forecast period.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of congestive heart failure treatment devices market is $11,897.97 million in 2020.

A. The forecast period for congestive heart failure treatment Devices market is 2021 to 2030.

A. The base year is 2020 in congestive heart failure treatment devices market

A. Top companies such as Abbot Laboratories (St. Jude Medical Inc.), Abiomed Inc., Berlin Heart GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation, Jarvik Heart Inc, Lepu Medical, Medtronic Plc, Microport Scientific Corporation, and Osypka Medical GmbH held a high market position in 2020.

A. Pacemakers segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period due to the technological advancements and new product launch and thus is expected to drive the segment

A. Increase in demand for new technologies in congestive heart failure treatment devices, advanced infrastructure for research & development and investments in healthcare is anticipated to drive the market in the forecast period.

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Congestive Heart Failure (chf) Treatment Devices Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2021–2030

Published in Feb 2022

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers